Martin George Sanda
#166,083
Most Influential Person Now
Martin George Sanda's AcademicInfluence.com Rankings
Martin George Sandabiology Degrees
Biology
#13468
World Rank
#17013
Historical Rank
Genetics
#1504
World Rank
#1607
Historical Rank
Molecular Biology
#2287
World Rank
#2321
Historical Rank
Download Badge
Biology
Martin George Sanda's Degrees
- PhD Molecular Biology Stanford University
- Masters Biochemistry University of California, San Francisco
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Martin George Sanda Influential?
(Suggest an Edit or Addition)Martin George Sanda's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The polycomb group protein EZH2 is involved in progression of prostate cancer (2002) (2596)
- Quality of life and satisfaction with outcome among prostate-cancer survivors. (2008) (1335)
- Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. (2000) (1326)
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options (2017) (683)
- Autoantibody signatures in prostate cancer. (2005) (606)
- alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. (2002) (597)
- Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. (2009) (585)
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. (1999) (506)
- Contemporary diagnosis and management of renal angiomyolipoma. (2002) (488)
- Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. (2002) (456)
- A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. (2011) (437)
- Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. (2005) (388)
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells (2019) (368)
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA (2011) (364)
- Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. (2010) (327)
- The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis (2012) (291)
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options (2018) (287)
- Prediction of erectile function following treatment for prostate cancer. (2011) (284)
- Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. (2003) (275)
- Prospective assessment of patient reported urinary continence after radical prostatectomy. (2000) (267)
- Molecular characterization of defective antigen processing in human prostate cancer. (1995) (239)
- Can urinary PCA3 supplement PSA in the early detection of prostate cancer? (2014) (234)
- Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States (2009) (229)
- The prostate health index selectively identifies clinically significant prostate cancer. (2015) (228)
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation (2014) (227)
- Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. (2007) (219)
- Demonstration of a rational strategy for human prostate cancer gene therapy. (1994) (214)
- Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. (2014) (213)
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. (2013) (211)
- Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. (2014) (211)
- Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. (2015) (207)
- Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. (1999) (204)
- A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness (2010) (202)
- Daily prostate targeting using implanted radiopaque markers. (2001) (199)
- Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. (1995) (178)
- Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer (2009) (178)
- Racial/ethnic disparities in the treatment of localized/regional prostate cancer. (2004) (160)
- Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study (2013) (147)
- Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. (2011) (143)
- Longitudinal Analysis of a Model to Predict Quality of Life in Prostate Cancer Patients and their Spouses (2008) (143)
- Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. (2015) (137)
- Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. (2016) (130)
- The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression (2004) (129)
- Humoral Immune Response to α-Methylacyl-CoA Racemase and Prostate Cancer (2004) (122)
- Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. (2003) (113)
- Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer (2017) (111)
- Genetic susceptibility of benign prostatic hyperplasia. (1994) (110)
- A comparison of ventilatory prostate movement in four treatment positions. (2000) (109)
- Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study. (2015) (99)
- The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. (2003) (92)
- Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. (2014) (91)
- Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. (2006) (91)
- Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI (2012) (90)
- Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. (2009) (88)
- [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. (2007) (85)
- Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer (2014) (85)
- Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer (2013) (85)
- Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma (2016) (82)
- Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies (2000) (79)
- Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer (2017) (74)
- Neoadjuvant Enzalutamide Prior to Prostatectomy (2016) (72)
- Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. (2004) (71)
- Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide (2010) (71)
- Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. (2005) (70)
- Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. (2001) (69)
- Early castration reduces prostatic carcinogenesis in transgenic mice. (1999) (68)
- Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. (2015) (67)
- Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. (2010) (67)
- Elevated α-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer (2004) (67)
- Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. (2000) (65)
- Concordance rates for benign prostatic disease among twins suggest hereditary influence. (1994) (64)
- Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. (2014) (63)
- Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. (2012) (62)
- Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. (2013) (61)
- Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival (2002) (61)
- Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. (2002) (60)
- Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. (1998) (60)
- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. (2008) (59)
- Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. (2006) (58)
- Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. (2000) (56)
- Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. (2002) (53)
- Patterns of care for radical prostatectomy in the United States from 2003 to 2005. (2008) (52)
- Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? (2001) (51)
- Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. (2009) (51)
- Tracking humoral responses using self assembling protein microarrays (2008) (48)
- Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. (2003) (48)
- Prostate cancer in a transgender woman 41 years after initiation of feminization. (2006) (47)
- Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. (2002) (47)
- Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer (2018) (47)
- Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells (2001) (46)
- Clinical and biological characteristics of familial benign prostatic hyperplasia. (1997) (45)
- Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. (2001) (45)
- Prognostic factors in lymph node-positive prostate cancer. (2005) (43)
- An Internet intervention for management of uncertainty during active surveillance for prostate cancer. (2011) (43)
- Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. (2014) (43)
- Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. (2018) (42)
- Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. (2008) (42)
- Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer (2011) (42)
- Partners’ Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment (2013) (42)
- Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. (2000) (40)
- Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. (2008) (40)
- The experiences of unpartnered men with prostate cancer: a qualitative analysis (2011) (39)
- Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery (2008) (39)
- Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy (2008) (37)
- Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer (2017) (37)
- Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. (1999) (37)
- Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. (2004) (36)
- Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4 (2017) (35)
- The role of active vaccination in cancer immunotherapy: lessons from clinical trials. (2015) (35)
- Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. (2004) (35)
- Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. (2018) (34)
- Use of quality indicators to evaluate the care of patients with localized prostate carcinoma (2003) (34)
- Collagen injection for the treatment of incontinence after cystectomy and orthotopic neobladder reconstruction in women. (2000) (34)
- Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. (2013) (34)
- A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. (2009) (33)
- Decision Support with the Personal Patient Profile‐Prostate: A Multicenter Randomized Trial (2018) (32)
- Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. (2002) (32)
- Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. (1992) (32)
- epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer (2019) (32)
- Uncertainty and perception of danger among patients undergoing treatment for prostate cancer (2013) (32)
- Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet (2010) (31)
- The TMPRSS 2 : ERG Rearrangement , ERG Expression , and Prostate Cancer Outcomes : A Cohort Study and Meta-analysis (2012) (30)
- Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. (2006) (30)
- Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. (2020) (29)
- Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. (1994) (29)
- [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. (2005) (29)
- Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. (2013) (28)
- Updating risk prediction tools: A case study in prostate cancer (2012) (28)
- Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. (2004) (27)
- Survivorship after prostate cancer treatment: spouses' quality of life at 36 months. (2013) (27)
- Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. (2001) (27)
- Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. (2014) (27)
- Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice (2010) (27)
- Selective detection of histologically aggressive prostate cancer (2012) (26)
- In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. (1992) (26)
- Detection of prostate cancer‐specific transcripts in extracellular vesicles isolated from post‐DRE urine (2017) (26)
- Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. (2011) (25)
- Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men (2015) (25)
- External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. (2017) (24)
- Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. (1991) (24)
- Histopathologic characterization of hereditary benign prostatic hyperplasia. (1996) (24)
- A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer (2019) (23)
- Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. (2003) (23)
- Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. (2013) (23)
- Circulating microRNAs in plasma among men with low‐grade and high‐grade prostate cancer at prostate biopsy (2019) (22)
- Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot‐Assisted Radical Prostatectomy (2016) (22)
- Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model (1995) (22)
- The ‘CaP Calculator’: an online decision support tool for clinically localized prostate cancer (2010) (21)
- Prospects for an SV40 vaccine. (2001) (21)
- Comparison of validated instruments measuring sexual function in men. (2010) (21)
- Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. (2004) (21)
- Satisfaction with information used to choose prostate cancer treatment. (2014) (20)
- Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. (2016) (18)
- Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. (2019) (18)
- Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer (2013) (17)
- Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. (1999) (17)
- RNA biomarkers to facilitate the identification of aggressive prostate cancer. (2015) (16)
- Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment (2017) (15)
- Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. (2009) (15)
- Ventilatory movement of the prostate during radiotherapy (2000) (15)
- MAXIMUM TUMOR DIMENSION PROVIDES A CLINICALLY USEFUL AND INDEPENDENTLY SIGNIFICANT MEASURE FOR PREDICTING PSA-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY (1999) (15)
- Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer (2018) (14)
- Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study (2017) (14)
- Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques (2018) (14)
- Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early-stage prostate cancer (2004) (14)
- The Role of the Transcription Factor SIM2 in Prostate Cancer (2011) (13)
- Evaluation of patient-reported quality-of-life outcomes after renal surgery. (2012) (13)
- Abstract CN03-03: Disparities in quality of life and satisfaction with outcome among prostate cancer survivors and their spouses (2009) (13)
- Antigen‐specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC (2002) (12)
- Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer (2004) (12)
- Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development (2000) (12)
- Stereotactic Body Radiation Therapy for Intermediate-risk Organ-confined Prostate Cancer: Interim Toxicity and Quality of Life Outcomes From a Multi-institutional Study (2012) (12)
- PD46-02 MULTICENTER EVALUATION OF THE PROSTATE HEALTH INDEX (PHI) FOR DETECTION OF AGGRESSIVE PROSTATE CANCER IN BIOPSY-NAÏVE MEN (2015) (12)
- Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. (2016) (11)
- Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response (2014) (11)
- A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer (2021) (11)
- Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. (2014) (10)
- Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. (2019) (10)
- Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. (2016) (10)
- Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review (2020) (9)
- Measuring Patient Satisfaction (2006) (8)
- Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. (2020) (8)
- High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells (2022) (8)
- Patient-Reported Quality of Life Outcomes in Intermediate-Risk Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy (2013) (7)
- Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands. (2019) (7)
- Gene therapy for urologic cancer. (1994) (7)
- Genetic factors associated with prostate cancer conversion from active surveillance to treatment (2021) (7)
- 1781 BENCHMARKS FOR OPERATIVE OUTCOMES OF ROBOTIC LAPAROSCOPIC AND OPEN RADICAL PROSTATECTOMY BASED ON RESULTS FROM A NATIONWIDE AMERICAN COHORT: THE HEALTH PROFESSIONALS FOLLOW-UP STUDY (2011) (7)
- 1185: Long-Term Outcomes Among Localized Prostate Cancer Survivors: HRQOL Changes 4 to 8 Years Following Brachytherapy, External Radiation and Radical Prostatectomy (2004) (7)
- Retroperitoneoscopy: effects of insufflation media on surrounding tissue during balloon rupture. (1995) (7)
- Stereotactic Radiotherapy for Organ-confined Prostate Cancer: Early Toxicity and Quality of Life Outcomes from a Multi-institutional Trial (2010) (7)
- Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer (2008) (7)
- 1847 [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY (2010) (7)
- Evolution of outcomes with the ileal hydraulic valve continent diversion: reevaluation of the Benchekroun catheterizable stoma (2004) (7)
- 1 THE TMPRSS 2 : ERG REARRANGEMENT , ERG EXPRESSION , AND PROSTATE CANCER OUTCOMES : A COHORT STUDY AND META-ANALYSIS (2012) (6)
- Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis (2019) (6)
- High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. (2019) (6)
- Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study. (2012) (6)
- 552: Patient-Reported Outcomes after Retropubic, Laparoscopic, or Robot-Assisted Prostatectomy: Results from a Prospective, Multi-Center Study (2007) (6)
- Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes (2018) (6)
- Partially circumventing peripheral tolerance for oncogene‐specific prostate cancer immunotherapy (2008) (6)
- Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence) (2013) (6)
- [18F]fluciclovine PET/CT for Preoperative Staging in Patients with Intermediate to High-Risk Primary Prostate Cancer. (2020) (5)
- Health-related quality of life in treatment for prostate cancer: looking beyond survival. (2004) (5)
- Evaluation of a 24‐gene signature for prognosis of metastatic events and prostate cancer‐specific mortality (2017) (5)
- Expanded Prostate Cancer Index Composite--Short Form (2020) (5)
- The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells (2015) (5)
- A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy (2019) (5)
- Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support (2019) (5)
- Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) for Measuring Health-Related Quality of Life Among Prostate Cancer Survivors (2011) (5)
- 1151: Perioperative Quality Care Indicators of Retropubic, Laparoscopic, and Robotic Prostatectomy: Results from a National, Multi-Center, Prospective Cohort (2006) (5)
- Trends in Surgical Management of Benign Prostatic Hyperplasia (2011) (4)
- In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. (2020) (4)
- Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study. (2012) (4)
- Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium (2021) (4)
- 11: Impact of Prostate Cancer Patient Treatment Outcome on HRQOL and Satisfaction with Cancer Care among Their Spouses (2007) (4)
- BLADDER NECK-SPARING TECHNIQUE ADVERSELY AFFECTS ANTI-TUMOR EFFICACY OF RADICAL PROSTATECTOMY IN PATHOLOGIC T3a PROSTATE CANCER (1999) (4)
- Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer (2019) (4)
- 18: Measuring Quality-of-Life after Surgery: Development and Validation of the Convalescence and Recovery Evaluation (CARE) (2007) (4)
- Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci (2022) (3)
- INCREASED POSITIVE YIELD OF CLINICALLY SIGNIFICANT PROSTATE CANCER WITH MRI PROMPTED BIOPSIES (2009) (3)
- Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer (2021) (3)
- Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4 (2009) (3)
- A safety-modified SV40 Tag developed for human cancer immunotherapy (2009) (3)
- RECOVERY AFTER ABDOMINAL AND PELVIC SURGERY (2008) (3)
- In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study. (2018) (3)
- Biological principles and clinical development of prostate cancer gene therapy. (1997) (3)
- Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. (2019) (3)
- Real-world use of epic for clinical practice (EPIC-CP) to assess patient-reported prostate cancer quality of life in the clinical setting. (2015) (2)
- Live longer but not better...yet. (2009) (2)
- 2106 BODY MASS INDEX AND PROSTATE SIZE IMPROVE PERFORMANCE OF A PROSTATE CANCER RISK CALCULATOR AT HIGH LEVELS OF SENSITIVITY FOR PREDICTING PROSTATE CANCER AT INITIAL PROSTATE BIOPSY: RESULTS FROM A PROSPECTIVE, MULTI-CENTER COHORT (2010) (2)
- Health related quality of life following 3D conformal external beam radiotherapy: treatment factors influence patient-reported outcome (2000) (2)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
- Comparative Effectiveness Study of Proton Therapy Versus IMRT for Definitive Treatment of Prostate Cancer Based on Patient-Reported Outcomes (2013) (2)
- 999 SELECTIVE DETECTION OF HISTOLOGICALLY AGGRESSIVE PROSTATE CANCER: VALIDATION BY PCPT COHORT DATA OF AN EDRN PREDICTIVE MODEL TO REDUCE UNNECESSARY PROSTATE BIOPSIES (2011) (2)
- 2055 PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS (2013) (2)
- PTP1B regulates lymphocytes responses androgen deprivation (2014) (2)
- 827: Salvage Therapy Adversely Effects Long-Term Hrqol among Localized Prostate Cancer Treatment Survivors (2005) (2)
- Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. (2019) (2)
- MP37-01 EXPANDED PROSTATE CANCER INDEX COMPOSITE-26 (EPIC-26) ONLINE: VALIDATION OF AN INTERNET-BASED INSTRUMENT FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER (2016) (2)
- Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (2)
- Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): Development and Validation of a Practical Health- Related Quality of Life Instrument for Use in the Routine Clinical Care of Prostate Cancer Patients (2013) (2)
- Genitourinary cancer committee (2001) (1)
- MP76-13 PROSTATE BIOPSY COSTS FOR PRIVATELY-INSURED MEN: IMPACT OF MAGNETIC RESONANCE IMAGE-GUIDANCE AND USE OF ANESTHESIA SERVICES (2018) (1)
- Nomogram predicting treatment-related sexual dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI). (2012) (1)
- Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. (2018) (1)
- Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer (2012) (1)
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment (2021) (1)
- Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro. (2017) (1)
- MP40-13 OPTIMIZED CLINICAL ALGORITHM TO COMBINE TESTING OF SERUM PHI AND URINARY PCA3 TO IMPROVE PROSTATE CANCER DETECTION BY REDUCING UNNECESARY BIOPSY (2018) (1)
- External Validation of Early Quality of Life (QOL) Declines Correlated with Late QOL after Intensity Modulated, Low Dose Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer within a Prospective Trial (2020) (1)
- 909: Neoadjuvant Hormone Therapy Impairs Long-term Sexual Outcome Among Younger Men that Undergo External Beam Radiotherapy for Localized Prostate Cancer (2004) (1)
- Advances in Brief The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression (2004) (1)
- Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model (2022) (1)
- PI-08 COMBINING URINE PCA3 AND TMPRSS2: ERG TESTS TO REFINE PROSTATE CANCER DETECTION – VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS (2015) (1)
- Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer (2022) (1)
- 2204: Early Complications Following Contemporary Brachytherapy for Prostate Cancer in a Multi-Institutional Study at High Volume Health Centers in the US (2006) (1)
- 2024 ROBOTIC RADIOSURGERY FOR ORGAN-CONFINED PROSTATE CANCER: EARLY TOXICITY OUTCOMES FROM A MULTI-INSTITUTIONAL TRIAL (2010) (1)
- MP76-06 USE AND EFFECTIVENESS OF PHARMACOLOGIC AND NON-PHARMACOLOGIC ERECTILE AIDS AMONG POST-PROSTATECTOMY PROSTATE CANCER SURVIVORS SEEKING TREATMENT FOR ERECTILE DYSFUNCTION: A PROSPECTIVE, MULTICENTER STUDY (2016) (1)
- 982 EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)1 IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION (2011) (1)
- 1535 PERSONALIZED PREDICTION OF ERECTION RECOVERY AFTER PRIMARY PROSTATE CANCER TREATMENT: VALIDATION IN THE COMMUNITY-BASED CAPSURE COHORT OF A PREDICTIVE MODEL DEVELOPED IN PROSTQA (2011) (1)
- Impact of Rectal Bleeding on Quality of Life Measures After Prostate Radiation Therapy: Comparison of the EPIC-26 and EPIC-CP Instruments (2015) (1)
- TMPRSS2-ERG FUSION PROSTATE CANCER PREVALENCE, ASSOCIATION WITH PSA DENSITY, AND HISTOLOGIC FEATURES IN A MULTI-CENTER U.S. COHORT OF MEN UNDERGOING PROSTATE BIOPSY (2008) (1)
- [-2]PROPSA FOR PROSTATE CANCER DETECTION: A PROSPECTIVE, MULTICENTER, NCI EARLY DETECTION RESEARCH NETWORK STUDY (2009) (1)
- UTILIZATION OF PHARMACOTHERAPY FOR ERECTILE DYSFUNCTION FOLLOWING SURGERY FOR PROSTATE CANCER (2008) (1)
- Pre-treatment nomogram to predict potency after treatment for localized prostate cancer. (2016) (1)
- NOMOGRAM PREDICTING BOWEL DYSFUNCTION FOR MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY, EXTERNAL‐BEAM RADIOTHERAPY, OR BRACHYTHERAPY: MP93‐03 (2017) (1)
- Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate cancer quality-of-life study. (2010) (1)
- A Branched DNA Assay for Detecting TMPRSS2-ERG Fusions. (2009) (1)
- In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. (2019) (1)
- 1772: Prostate Size, Obesity, and Neoadjuvant Hormone Therapy affect Hrqol in a Prospective, Multi-Center Study of Prostatectomy, External Radiotherapy, or Brachytherapy for Prostate Cancer (2007) (1)
- Nomogram predicting treatment-related urinary incontinence for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (PI). (2012) (1)
- COMPARISON OF VALIDATED INSTRUMENTS TO MEASURE SEXUAL FUNCTION IN A COHORT OF PREOPERATIVE PROSTATE CANCER PATIENTS (2008) (1)
- Quality of life after primary treatment for localized prostate cancer: long-term considerations. (2015) (1)
- Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy (2019) (1)
- Covariate adjustment in continuous biomarker assessment (2021) (1)
- Early Adoption of MRI-Guided Prostate Biopsies Rose Rapidly among Men with Private Health Insurance (2017) (0)
- Characteristics, Treatment and Outcomes of Patients with Primary Urethral Cancer: A Multi-Center Review over Two Decades (2022) (0)
- Cause-specific survival is high following radiotherapy or surgery for Gleason score 8–10 prostate cancer (2004) (0)
- 694 ALLEVIATION VERSUS INDUCTION OF URINARY OBSTRUCTION OR INCONTINENCE BY PROSTATE CANCER TREATMENT THE PIVOTAL ROLE OF PRETREATMENT URINARY SYMPTOMS (2012) (0)
- Abstract 6081: Integrative genomic analysis of primary prostate tumors and corresponding lymph node metastases (2023) (0)
- Gene therapy for urologic cancer: Basic principles, prospects, and limitations (2005) (0)
- Dose to the Inferior Rectum Has the Strongest Association With Patient-Reported Bowel Quality of Life (QOL) After External Beam Radiation Therapy (EBRT) for Prostate Cancer (2013) (0)
- Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment (2022) (0)
- MP02-09 TARGETED SEQUENCING OF PROSTATE CANCER-ASSOCIATED RNAS IN EXTRACELLULAR VESICLES FROM POST-DRE URINE (2016) (0)
- USE OF BASELINE, PRE-OPERATIVE, CLINICALLY ACCESSIBLE PARAMETERS TO PREDICT THERAPEUTIC EFFICACY OF RADICAL PROSTATECTOMY (1999) (0)
- Transcriptome analysis identifies networks and key drivers in tumor microenvironment for metastatic castration-resistant prostate cancer (2022) (0)
- Covariate‐specific evaluation of continuous biomarker (2023) (0)
- 21 PCA3 and PCA3/TERG add further predictive value to the PCPT risk calculator amongst non-African American men, but not amongst African Americans in the Early Detection Research Network (EDRN) (2015) (0)
- 194 Predictors of Patient and Partner Reported Sexual Satisfaction Following Radical Prostatectomy (2017) (0)
- Association of race with receipt of definitive therapy for high risk prostate cancer in older men. (2021) (0)
- Patient-reported Quality of Life in Prostate Cancer Patients Treated With 3D Conformal Intensity Modulated or Proton Beam Radiation Therapy (2012) (0)
- Prostate cancer treatments: Assessing effects on quality of life (2006) (0)
- 676: Obesity Affects Health Related Quality of Life at Baseline Before and in Recovery after Radical Retropubic Prostatectomy (2005) (0)
- LONG‐TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: PD18‐03 (2017) (0)
- Abstract A29: The TMPRSS2:ERG gene fusion, ERG expression and prostate cancer outcomes: A cohort study and meta-analysis (2011) (0)
- PD38-11 IMPACT OF PREBIOPSY PROSTATE MRI ON BIOPSY RESULTS, INITIAL TREATMENT, AND PROSTATECTOMY OUTCOMES FOR MEDICARE-ELIGIBLE PROSTATE CANCER PATIENTS (2020) (0)
- Outcomes session. (2012) (0)
- Patient-Reported Outcomes for Quality of Life (QOL) by Expanded Prostate Cancer Index (EPIC) 15 Years Posttreatment (2014) (0)
- 592 QUALITY OF LIFE AFTER ROBOT ASSISTED COMPARED TO OPEN RADICAL PROSTATECTOMY: INITIAL EXPERIENCE IN THE COMMUNITY SETTING (2010) (0)
- 1327: Current Status of Clinical Trials in Urothelial Cancers: A Summary from the ACOSOG Gu Working Group (2005) (0)
- Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (0)
- Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131. (2010) (0)
- Dynamic correlation of serum C-reactive protein (CRP) levels with serum prostate-specific antigen (PSA) levels in patients with prostate cancer (PCa) on androgen deprivation therapy (ADT). (2016) (0)
- Focal Nodular Enhancement on 3D MRI of Cystic Renal Lesions Predicts Malignancy (2006) (0)
- Safety of high dose rate prostate brachytherapy in patients with high baseline international prostate symptom scores. (2019) (0)
- The Prostate 70 : 1002 ^ 1011 ( 2010 ) AndrogenAblationAugmentsHuman HLA 2 . 1-RestrictedT cell Responses to PSASelf-Antigen inTransgenicMice (2010) (0)
- Neoadjuvant Hormone Therapy (NHT) Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multi-Center Prospective Study (2005) (0)
- Exploiting the Good Guys: Th1 Antiviral & Antitumor Human & Mouse NKT Cells (2010) (0)
- 1407: Measuring Anti-Amacr Humoral Response as a Serum Assay to Distinguish Aggressive from Indolent Prostate Cancer (2005) (0)
- 1: Determinants of Satisfaction with Outcome in a Prospective, Multi-Center Study of Prostatectomy, External Radiotherapy, or Brachytherapy for Early Stage Prostate Cancer (2007) (0)
- PERSONALIZED DECISION SUPPORT FOR LOCALIZED PROSTATE CANCER: RESULTS OF A MULTI‐SITE RANDOMIZED TRIAL: PD06‐03 (2017) (0)
- Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine (2011) (0)
- UTILIZATION OF DEFERRED TREATMENT/WATCHFUL WAITING AMONG PROSTATE CANCER SURVIVORS IN THE PHYSICIANS' HEALTH STUDY (2008) (0)
- Metabolic profiling of T-cell differentiation and tolerance (115.5) (2012) (0)
- Preoperative staging in high-risk prostate cancer patients using [18F] fluciclovine PET/CT (2019) (0)
- Distinct transcriptome of regulatory T cells in prostate cancer (162.18) (2012) (0)
- Personalized peptide-based vaccine design for prostate cancer immunotherapy (2012) (0)
- PD15-02 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY (2023) (0)
- Predicting return of erectile function following external beam radiotherapy or brachytherapy for prostate cancer using EPIC-CP. (2016) (0)
- Quality of Life Following Management of Localized Prostate Cancer (2018) (0)
- DISCRIMINATION OF CARE TO PATIENT DIFFERENCES: A USEFUL TOOL FOR EVALUATING QUALITY? (2008) (0)
- 665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY (2013) (0)
- MP26-20 UTILITY OF DIGITAL RECTAL EXAM FOR PROSTATE CANCER SCREENING AMONG MEN WITH LOW PSA VALUES (2021) (0)
- PREDICTING ERECTION RECOVERY AFTER PROSTATECTOMY: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM (2009) (0)
- DETERMINANTS OF LONG-TERM RETENTION OF PROSTATE CANCER PATIENTS IN ACTIVE SURVEILLANCE MANAGEMENT PROGRAMS (2008) (0)
- Mxi1,aMycAntagonist,SuppressesProliferationof DU145HumanProstateCells (2001) (0)
- 1132 THE EXPANDED PROSTATE CANCER INDEX COMPOSITE FOR CLINICAL PRACTICE (EPIC-CP) IS SENSITIVE TO TREATMENT-RELATED QUALITY OF LIFE CHANGES OVER TIME VALIDATION USING THE PROST-QA COHORT (2012) (0)
- Immunogenic Peptides Derived from the Transcription Factor ERG as a Vaccine for Prostate Cancer (162.17) (2012) (0)
- 990 PROGRESSION AND TREATMENT IN A MULTI-INSTITUTIONAL, PROSPECTIVE ACTIVE SURVEILLANCE STUDY: RESULTS FROM CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS) (2012) (0)
- 465: Impact of Post-Prostatectomy Urethral Strictures on Urinary and Sexual Health Related Quality of Life (2006) (0)
- Optimizing anti‐tumor immunity: Mechanisms and reversion of systemic iNKT defects in murine prostate cancer (2008) (0)
- 1812 SURGEON VARIANCE IN PATIENT-REPORTED AND CLINICAL OUTCOMES OF RETROPUBIC, LAPAROSCOPIC, OR ROBOTIC RADICAL PROSTATECTOMY (2012) (0)
- Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS). (2013) (0)
- Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer (2014) (0)
- Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: Quality of life outcomes. (2018) (0)
- Abstract 4241: Circulating microRNAs in plasma of men screened for prostate cancer (2017) (0)
- UTILIZATION OF MEDICATIONS AND DEVICES FOR ERECTILE DYSFUNCTION AFTER PROSTATE CANCER TREATMENT: RESULTS FROM THE MULTICENTER PROSTQA CONSORTIUM (2009) (0)
- Is androgen suppression therapy associated with early onset of fatal myocardial infarction? (2008) (0)
- OR.87. Optimizing Anti-tumor Immunity: Reversing Systemic iNKT Cell Immunoregulatory Defects in Murine Prostate Cancer (2008) (0)
- PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST‐QA/RP2 CONSORTIUM: PD18‐08 (2017) (0)
- 386 PCA3 and T2-ERG add further predictive and clinical benefit to the detection of prostate cancer in men of various ages in the early detection research network (EDRN) (2016) (0)
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells (2019) (0)
- 1218 INCORPORATION OF BODY MASS INDEX AND PROSTATE SIZE INTO A NOMOGRAM FOR SELECTING PATIENTS FOR INITIAL PROSTATE BIOPSY: VALIDATION IN THE PROSTATE CANCER PREVENTION TRIAL (2012) (0)
- 437 NOMOGRAM PREDICTING URINARY INCONTINENCE FOR MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY, EXTERNAL-BEAM RADIOTHERAPY, AND BRACHYTHERAPY (2013) (0)
- Normal Prostate E-Cadherin Distinguishes Prostate Cancer from Matched Posttranslational Truncation and Inactivation of Human (2013) (0)
- MP23-19 DECISION REGRET, ADVERSE OUTCOMES AND TREATMENT CHOICE IN MEN WITH LOCALIZED PROSTATE CANCER: RESULTS FROM A MULTI-SITE RANDOMIZED TRIAL (2020) (0)
- Interval estimation for operating characteristic of continuous biomarkers with controlled sensitivity or specificity (2021) (0)
- MP35-10 DETECTION OF PROSTATE CANCER-ASSOCIATED TRANSCRIPTS IN URINARY EXTRACELLULAR VESICLES (2018) (0)
- [18F]fluciclovine PET/CT versus multiparametric MRI assessment of seminal vesicle invasion and extracapsular extension in patients with primary prostate cancer. (2020) (0)
- Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. (2021) (0)
- PROSTATE CANCER STAGING: EVALUATION OF NOMOGRAM PREDICTING UNFAVORABLE PATHOLOGY (1999) (0)
- Assessment of urinary HRQOL in post-prostatectomy patients using epic A patient-reported validated instrument (2001) (0)
- POPULATION‐LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI‐GUIDED PROSTATE BIOPSY: MP08‐09 (2017) (0)
- MP14-17 PREDICTING ERECTILE FUNCTION FOLLOWING RADIATION THERAPY FOR PROSTATE CANCER AT THE POINT OF CARE (2016) (0)
- Adult UrologyOncology: Prostate/Testis/Penis/UrethraEditorial Comment (2008) (0)
- Nomogram predicting treatment-related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI). (2012) (0)
- 2206 THE NCI EARLY DETECTION RESEARCH NETWORK (EDRN) URINARY PCA3 VALIDATION TRIAL (2012) (0)
- Antigen-SpecificTumorVaccine Efficacy InVivo Against ProstateCancerwith LowClass IMHC (2002) (0)
- Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance (2022) (0)
- DISCERNING RISK OF CLINICALLY SIGNIFICANT VERSUS INDOLENT PROSTATE CANCER PRIOR TO BIOPSY: PREDICTIVE MODEL FROM A MULTI-CENTER COHORT (2009) (0)
- 824: Neoadjuvant Hormone Therapy (NHT) Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multi-Center Prospective Study (2005) (0)
- Further perspectives on treating localized prostate cancer. (2009) (0)
- THE IMPACT OF BLADDER NECK SPARING AND NERVE SPARING ON URINARY FUNCTION AND CANCER CONTROL ASSOCIATED WITH RADICAL PROSTATECTOMY (1999) (0)
- Targeted RNA Sequencing of FFPE Prostate Biopsies and Matched Prostatectomies (2017) (0)
- MP35-06 MULTI-CENTER PROSPECTIVE STUDY OF PROSTATE HEALTH INDEX (PHI) TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH (2018) (0)
- 473: Racial Variations in the Utilization of Pelvic Lymph Node Dissection in Men Receiving a Radical Prostatectomy for Localized/Regional Prostate Cancer (2004) (0)
- Abstract 1819: Quality of life among prostate cancer survivors in the Physicians’ Health Study (2010) (0)
- Abstract 4451: The NCI Early Detection Research Network (EDRN) urinary PCA3 validation trial (2012) (0)
- Gene expression profile of Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) reveals murine targets for preclinical development of human prostate cancer therapy (2007) (0)
- Contemporary Clinical Trials of Prostate Cancer Immunotherapy (2004) (0)
- Breaking immune tolerance to prostate-associated tumor antigens through Tim-1 receptor (162.20) (2012) (0)
- 2158 COMBINING TMPRSS2:ERG AND PCA3 IN POST-DRE URINE WITH SERUM PSA TO IDENTIFY PROSTATE BIOPSY CANDIDATES: DEVELOPMENT AND VERIFICATION OF A CLINICALLY PRACTICAL ALGORITHM (2010) (0)
- MP51-10 PREDICTORS OF FAVORABLE URINARY OUTCOMES AFTER PROSTATE CANCER TREATMENT (2014) (0)
- Abstract 2701: Multivariate transcriptome analysis identifies networks and key drivers of metastatic castration-resistant prostate cancer (2022) (0)
- Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment (2014) (0)
- MP83-19 REAL-WORLD USE OF EPIC FOR CLINICAL PRACTICE (EPIC-CP) TO ASSESS PATIENT-REPORTED PROSTATE CANCER QUALITY-OF-LIFE IN THE CLINICAL SETTING (2015) (0)
- 137 EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION (2010) (0)
- Cancer Therapy: Preclinical Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer (2009) (0)
- AbstractDaily prostate targeting using implanted radiopaque markers (2001) (0)
- Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence. (2009) (0)
- PREDICTING URINARY FUNCTION AFTER PROSTATE CANCER TREATMENT: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM (2009) (0)
- Patient Reported Quality of Life Outcomes after HDR Brachytherapy Between Small (<60cc) and Large (≥ 60cc) Prostate Glands (2018) (0)
- MP67-04 PREOPERATIVE 18 F-FLUCICLOVINE PET/CT FINDINGS MAY BE PREDICTIVE OF POST-OPERATIVE PROSTATE-SPECIFIC ANTIGEN (PSA) IN PATIENTS WITH HIGH RISK PROSTATE CANCER (2020) (0)
- Providing practitioner-specific outcomes is associated with higher patient satisfaction with information about prostate cancer treatment. (2006) (0)
- MP-3.15: Patterns of Care for Radical Prostatectomy in the United States from 2003-2005 (2008) (0)
- Convalescence And Recovery Evaluation (2016) (0)
- Prostate Cancer Screening and Surveillance—Reply (2009) (0)
- MP21-12 PCA3 AND T2:ERG ADD FURTHER PREDICTIVE AND CLINICAL BENEFIT TO THE DETECTION OF PROSTATE CANCER IN MEN OF VARIOUS AGES IN THE EARLY DETECTION RESEARCH NETWORK (EDRN) (2016) (0)
- MP4-04 CLINICAL OUTCOMES OF CONSERVATIVELY MANAGED PROSTATE CANCER AMONG AFRICAN AMERICAN MEN (2015) (0)
- Appraisal and quality of life of partners of prostate cancer survivors 24 months after treatment: (548132012-039) (2010) (0)
- 905: The Prevalence and Outcome of Therapy for Erectile Dysfunction 4 to 8 Years Following Brachytherapy, External Radiation and Radical Prostatectomy for Localized Prostate Cancer (2004) (0)
- A PATIENT‐CENTERED PRACTICE CHANGE: FINDING THE BEST APPROACH FOR PROSTATE CANCER DECISION SUPPORT: MP69‐18 (2017) (0)
- Prostate Cancer for Dummies (2005) (0)
- 1077 INTERNET-BASED EVALUATION OF QUALITY-OF-LIFE OUTCOMES AFTER ROBOTIC, LAPAROSCOPIC, AND OPEN RADICAL OR PARTIAL NEPHRECTOMY (2011) (0)
- Looking for Biomarkers for Prostate Cancer Early Detection (2009) (0)
- PD23-08 EVALUATION OF FLUCICLOVINE (FACBC) PET SCAN FOR STAGING HIGH-RISK PROSTATE CANCER BEFORE PRIMARY TREATMENT (2019) (0)
- Mxi 1 , aMycAntagonist , Suppresses Proliferationof DU 145 HumanProstateCells (0)
- PD40-06 DISPARITIES IN USE OF PREBIOPSY PROSTATE MAGNETIC RESONANCE IMAGING FOR MEDICARE-ELIGIBLE PROSTATE CANCER PATIENTS (2020) (0)
- MP6-02 LOCATION OF DISEASE DOES NOT IMPACT PCA3'S ABILITY TO PREDICT CANCER ON BIOPSY (2015) (0)
- MP62-10 PROSTATE HEALTH INDEX IN PREDICTING GRADE RECLASSIFICATION ON BIOPSY FOR MEN ON ACTIVE SURVEILLANCE (2021) (0)
- 336 Nationwide Utilization of Reconstructive Urological Procedures to Mitigate Sexual and Urinary Complications Following Radical Prostatectomy (2018) (0)
- 1605: Prostate Cancer Physician Performance Measured by Patient-Reported Ratings of Practitioner Manner/Skill and by Treatment-Related Adverse Events (2006) (0)
- Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry. (2013) (0)
- 1403: Nodular Enhancement on Magnetic Resonance Imaging of Cystic Renal Lesions Predicts Malignancy (2005) (0)
- Comprehensive Comparison of Heal th-Related Qual i ty of Li fe Af ter Contemporary Therapies for Local ized Prostate Cancer (2001) (0)
- 1671: Association of Race, Cancer Severity, Pre-Treatment Quality of Life, and Patient Optimism/Pessimism with Patient Selection of Primary Prostate Cancer Treatment (2005) (0)
- PD46-05 MULTI-CENTER PROSPECTIVE STUDY OF URINE RNA TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH (2015) (0)
- Expanded Prostate Cancer Index Composite Questionnaire (2018) (0)
- Bladder neck-sparing radical prostatectomy and positive margins (2001) (0)
- The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells (2015) (0)
- UROLOGICAL ONCOLOGY: PROSTATE CANCER Autoantibody Signatures in Prostate Cancer (2006) (0)
- 388: Determinants of Patient Satisfaction Following Contemporary Therapy for Localized Prostate Cancer: Characterizing the Quality of Cancer Care and the Clinical Relevance of Long-Term HRQOL Outcomes (2004) (0)
- Multi-institutional Prospective Evaluation of Bowel Quality of Life after Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated with Patient Reported Outcomes (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Martin George Sanda?
Martin George Sanda is affiliated with the following schools:
